Tumor necrosis factor inhibitors for rheumatoid arthritis

Bulletin on the Rheumatic Diseases

Volumn 48, Issue 3, 1999, Pages 1-4

  Jones, Richard E ^a   Moreland, Larry W ^a  

^a Center for Palliative Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIBODY; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOBIOLOGY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033019872     PISSN: 00075248     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Keffer J, Probert L, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
2. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type 2 collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha.beta and IL-1RA. Arthritis Rheum 1996;39:797-809.
3. Wooley PH, Dutcher J, Widmer MB, et al: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type 2 collagen-induced arthritis in mice. J Immunol 1993;11:6602-7.
4. Moreland LW, Baumgartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
5. Moreland LW, Schiff MH, Baumgartner SW, et al: Recombinant human tumor necrosis factor receptor (p75):Fc fusion protein in rheumatoid arthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Int Med 1999;130:478-86.
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al: Phase 2/3 trial of TNF receptor p75 fusion protein (TNFR:Fc; Enbrel™) in combination with methotrexate in RA patients. Arthritis Rheum 1998;41(9 Suppl)S189,A939.
7. Felson DT, Anderson JJ, Boers M, et al: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
8. Lovell DJ, Giannini EH, Whitmore JB, Soffes L, Finck BK: Safety and efficacy of tumor necrosis factor receptor p75 fusion protein (TNFR:FC; Enbrel™) in polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 1998;41(9 Suppl)S130, A584.
9. Moreland LW, Baumgartner SW, Tindall E, et al: Long term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel™) in DMARD refractory rheumatoid arthritis (RA). Arthritis Rheum 1998:41(9 Suppl):S364,A1987.
10. Elliott MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor. Arthritis Rheum 1993;36:1681-90.
11. Elliott MJ, Maini RN, Feldmann M, et al: Repeated therapy with monoclonal antibody to tumour necrosis factor (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
12. Elliot MJ, Maini RN, Feldmann M, et al: Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
13. Maini RN, Breedveld FC, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
14. Lipsky P, St. Clair W, Kavanaugh A, et al: Long-term control of signs and symptoms of rheumatoid arthritis with chimeric monoclonal anti-TNF alpha antibody (infliximab) in patients with active disease on methotrexate. Arthritis Rheum 1998:41(9 Suppl)S364, A1988.
15. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldman M, Maini RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin 1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
16. Tak PP, Taylor PC, Breedveld FC, et al: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.